Guggenheim initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $20 price target The company is and should remain the dominant provider of minimal residual disease blood cancer tests, the analyst tells investors in a research note. The firm sees a path for sustained revenue growth for Adaptive due to continued market conversion, penetration into different indications, and price increases. The shares trade at a “notable discount” to other leading cancer specialty lab companies, contends Guggenheim.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies initiated with a Buy at Guggenheim
- 3 Stocks Flashing Strong Buy Signals on Technical Charts
- Adaptive Biotechnologies: Strategic Shift and Financial Realignment Support Buy Rating
- Adaptive Biotechnologies: Strategic Flexibility and Robust MRD Growth Drive Buy Rating
- Adaptive Biotechnologies down 5% after Genentech pact terminated